Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.
Press releases published on August 8, 2025
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND …
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and …
Monroe Capital Corporation Schedules Second Quarter 2025 Earnings Release
CHICAGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (the “Company”) (NASDAQ: MRCC) announced today that it will report its second quarter ended June 30, 2025 financial results on Monday, August 11, 2025, after the close of the financial …
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera ( …
Femasys Announces Second Quarter Financial Results for 2025
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth …
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advancements achieved …
Commerce to Present at Upcoming Investor Conference
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver …
Capital Clean Energy Carriers Corp. Announces Annual Meeting of Shareholders
ATHENS, Greece, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) (the “Corporation” or “CCEC”) has called an annual meeting of shareholders to be held at the Corporation’s headquarters in Greece …
Phunware Reports Second Quarter 2025 Financial Results
Delivers Strong First Half with Key Product Milestones and Customer Momentum Strong Liquidity Powering New Technology Improvements, AI Integration and Corporate Initiatives AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Phunware, Inc. (“Phunware” or the …
Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury …
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a …
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended …